These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 14534919

  • 1. Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease.
    Mizuno Y, Yanagisawa N, Kuno S, Yamamoto M, Hasegawa K, Origasa H, Kowa H, Japanese Pramipexole Study Group.
    Mov Disord; 2003 Oct; 18(10):1149-56. PubMed ID: 14534919
    [Abstract] [Full Text] [Related]

  • 2. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial.
    Möller JC, Oertel WH, Köster J, Pezzoli G, Provinciali L.
    Mov Disord; 2005 May; 20(5):602-10. PubMed ID: 15726540
    [Abstract] [Full Text] [Related]

  • 3. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease.
    Hauser RA, Schapira AH, Rascol O, Barone P, Mizuno Y, Salin L, Haaksma M, Juhel N, Poewe W.
    Mov Disord; 2010 Nov 15; 25(15):2542-9. PubMed ID: 20669317
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease.
    Linazasoro G, Spanish Dopamine Agonists Study Group.
    J Neurol; 2004 Mar 15; 251(3):335-9. PubMed ID: 15015015
    [Abstract] [Full Text] [Related]

  • 8. Twice-daily, low-dose pramipexole in early Parkinson's disease: a randomized, placebo-controlled trial.
    Kieburtz K, Parkinson Study Group PramiBID Investigators.
    Mov Disord; 2011 Jan 15; 26(1):37-44. PubMed ID: 20925067
    [Abstract] [Full Text] [Related]

  • 9. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
    Castro-Caldas A, Delwaide P, Jost W, Merello M, Williams A, Lamberti P, Aguilar M, Del Signore S, Cesaro P, Parkinson-Control Study Group.
    Mov Disord; 2006 Apr 15; 21(4):500-9. PubMed ID: 16267842
    [Abstract] [Full Text] [Related]

  • 10. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
    Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, McDermott M, Seibyl J, Weiner W, Musch B, Kamp C, Welsh M, Shinaman A, Pahwa R, Barclay L, Hubble J, LeWitt P, Miyasaki J, Suchowersky O, Stacy M, Russell DS, Ford B, Hammerstad J, Riley D, Standaert D, Wooten F, Factor S, Jankovic J, Atassi F, Kurlan R, Panisset M, Rajput A, Rodnitzky R, Shults C, Petsinger G, Waters C, Pfeiffer R, Biglan K, Borchert L, Montgomery A, Sutherland L, Weeks C, DeAngelis M, Sime E, Wood S, Pantella C, Harrigan M, Fussell B, Dillon S, Alexander-Brown B, Rainey P, Tennis M, Rost-Ruffner E, Brown D, Evans S, Berry D, Hall J, Shirley T, Dobson J, Fontaine D, Pfeiffer B, Brocht A, Bennett S, Daigneault S, Hodgeman K, O'Connell C, Ross T, Richard K, Watts A, Parkinson Study Group.
    Arch Neurol; 2004 Jul 15; 61(7):1044-53. PubMed ID: 15262734
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The effect of deprenyl and levodopa on the progression of Parkinson's disease.
    Olanow CW, Hauser RA, Gauger L, Malapira T, Koller W, Hubble J, Bushenbark K, Lilienfeld D, Esterlitz J.
    Ann Neurol; 1995 Nov 15; 38(5):771-7. PubMed ID: 7486869
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pramipexole and ropinirole for Parkinson's disease.
    Med Lett Drugs Ther; 1997 Nov 21; 39(1014):109-10. PubMed ID: 9398824
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Pramipexole, a nonergot dopamine agonist, is effective against rest tremor in intermediate to advanced Parkinson's disease.
    Künig G, Pogarell O, Möller JC, Delf M, Oertel WH.
    Clin Neuropharmacol; 1999 Nov 21; 22(5):301-5. PubMed ID: 10516884
    [Abstract] [Full Text] [Related]

  • 18. Pramipexole v. levodopa as initial treatment for Parkinson's disease: a randomized clinical-economic trial.
    Noyes K, Dick AW, Holloway RG, Parkinson Study Group.
    Med Decis Making; 2004 Nov 21; 24(5):472-85. PubMed ID: 15358996
    [Abstract] [Full Text] [Related]

  • 19. Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease.
    Clarke C E, Speller J M, Clarke J A.
    Cochrane Database Syst Rev; 2000 Nov 21; 2000(3):CD002259. PubMed ID: 10908539
    [Abstract] [Full Text] [Related]

  • 20. Pramipexole in Parkinson's disease. A short-term study using the combined levodopa-dopamine agonist test.
    Fabbrini G, Barbanti P, Aurilia C, Pauletti C, Meco G.
    Funct Neurol; 2002 Nov 21; 17(4):199-201. PubMed ID: 12675263
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.